GPER signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1β/IL1R1 response

Scientific Reports

Volumn 6, Issue , 2016, Pages

  De Marco, Paola ^a   Lappano, Rosamaria ^a   Francesco, Ernestina Marianna De ^a   Cirillo, Francesca ^a   Pupo, Marco ^a,c   Avino, Silvia ^a   Vivacqua, Adele ^a   Abonante, Sergio ^b   Picard, Didier ^c   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b Regional Hospital   (Italy)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; IL1R1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA;

BREAST TUMOR; FEMALE; FIBROBLAST; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKIN-1BETA; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, INTERLEUKIN-1 TYPE I; SIGNAL TRANSDUCTION;

EID: 84963986362     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24354     Document Type: Article

References (60)

1. Erez, N., Glanz, S., Raz, Y., Avivi, C. & Barshack, I. Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res. Commun. 437, 397-402 (2013).
2. Han, Y., Zhang, Y., Jia, T. & Sun, Y. Molecular mechanism underlying the tumor-promoting functions of carcinoma-associated fibroblasts. Tumor Biol. 36, 1385-1394 (2015).
3. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nature Rev Cancer 6, 392-401 (2006).
4. Ma, X. J., Dahiya, S., Richardson, E., Erlander, M. & Sgroi, D. C. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 11, R7 (2009).
5. Servais, C. & Erez, N. From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J. Pathol. 229, 198-207 (2013).
6. Weber, A., Wasiliew, P. & Kracht, M. Interleukin-1beta (IL-1beta) processing pathway. Sci. Signal 3 (2010).
7. Dinarello, C. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
8. Dinarello, C. A. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur. J. Immunol. 41, 1203-1217 (2011).
9. Apte, R. N. et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 25, 387-408 (2006).
10. Abrahamsson, A., Morad, V., Saarinen, N. M. & Dabrosin, C. Estradiol, tamoxifen, and flaxseed alter IL-1β and IL-1Ra levels in normal human breast tissue in vivo. J. Clin. Endocrinol. Metab. 97, E2044-54 (2012).
11. Lindahl, G., Saarinen, N., Abrahamsson, A. & Dabrosin, C. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. Cancer Res. 71, 51-60 (2011).
12. Elaraj, D. M. et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin. Cancer Res. 12, 1088-96 (2006).
13. Lewis, A. M., Varghese, S., Xu, H. & Alexander, H. R. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl. Med. 4, 48 (2006).
14. Franco-Barraza, J. et al. "Actin cytoskeleton participation in the Onset of IL-1β induction of an invasivemesenchymal-like phenotype in epithelial MCF-7 Cells". Archives of Medical Research 41, 170-181 (2010).
15. Perez-Yepez, E. A., Ayala-Sumuano, J. T., Reveles-Espinoza, A. M. & Meza, I. Selection of a MCF-7 Breast Cancer Cell Subpopulation with High Sensitivity to IL-1β : Characterization of and Correlation between Morphological and Molecular Changes Leading to Increased Invasiveness. Int. J. Breast Cancer 2012, 609148 (2012).
16. Jia, M., Dahlman-Wright, K. & Gustafsson, J. A. Estrogen receptor alpha and beta in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 29, 557-68 (2015).
17. Prossnitz, E. R. & Maggiolini, M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol. Cell. Endocrinol. 308, 32-38 (2009).
18. Lappano, R. & Maggiolini, M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 10, 47-60 (2011).
19. Maggiolini, M. & Picard, D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J. Endocrinol. 204, 105-114 (2010).
20. Pandey, D. P. et al. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 28, 523-32 (2009).
21. De Francesco, E. M. et al. GPER mediates activation of HIF1α /VEGF signaling by estrogens. Cancer Res. 15, 4053-64 (2014).
22. Lappano, R. et al. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. Breast Cancer Res. 14, R12 (2012).
23. Lappano, R. et al. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Curr. Cancer Drug Targets 12, 531-42 (2012).
24. Vivacqua, A. et al. GPER mediates the Egr-1 expression induced by 17β -estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Res. Treat. 133, 1025-35 (2012).
25. Pupo, M. et al. The nuclear localization signal is required for nuclear GPER translocation and function in breast Cancer-Associated Fibroblasts (CAFs). Mol. Cell. Endocrinol. 376, 23-32 (2013).
26. Santolla, M. F. et al. SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer. Cell Death Dis. 6, e1834 (2015).
27. De Francesco, E. M. et al. GPER mediates cardiotropic effects in spontaneously hypertensive rat hearts. Plos One 8, e69322 (2013).
28. Prossnitz, E. R. & Barton, M. Estrogen biology: New insights into GPER function and clinical opportunities. Mol. Cell. Endocrinol. 389, 71-83 (2014).
29. Wang, C. et al. GPR30 contributes to estrogen-induced thymic atrophy. Mol. Endocrinol. 22, 636-648 (2008).
30. Jiang, Q. F. et al. 17β-estradiol promotes the invasion and migration of nuclear estrogen receptor-negative breast cancer cells through cross-talk between GPER1 and CXCR1. J. Steroid Biochem. Mol. Biol. 138, 314-24 (2013).
31. He, Y. Y., Cai, B., Yang, Y. X., Liu, X. L. & Wan, X. P. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogenactivated protein kinase pathway. Cancer Sci. 100, 1051-61 (2009).
32. Whipple, C. A. Tumor talk: understanding the conversation between the tumor and its microenvironment. Cancer Cell Microenviron. 2, e773 (2015).
33. Tamm-Rosenstein, K., Simm, J., Suhorutshenko, M., Salumets, A. & Metsis, M. Changes in the transcriptome of the human endometrial Ishikawa cancer cell line induced by estrogen, progesterone, tamoxifen, and mifepristone (RU486) as detected by RNAsequencing. Plos One 8, e68907 (2013).
34. Mehrotra, S., Morimiya, A., Agarwal, B., Konger, R. & Badve, S. Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J. Pathol. 208, 356-63 (2006).
35. Malekshah, O. M., Lage, H., Bahrami, A. R., Afshari, J. T. & Behravan, J. PXR and NF-κ B correlate with the inducing effects of IL-1β and TNF-α on ABCG2 expression in breast cancer cell lines. Eur. J. Pharm. Sci. 47, 474-80 (2012).
36. Vicente-Manzanares, M., Koach, M. A., Whitmore, L., Lamers, M. L. & Horwitz, A. F. Segregation and activation of myosin IIB creates a rear in migrating cells. J. Cell. Biol. 183, 543-54 (2008).
37. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-52 (2009).
38. Cirri, P. & Chiarugi, P. Cancer associated fibroblasts: the dark side of the coin. Am. J. Cancer Res. 1, 482-97 (2011).
39. Luker, K. E. & Luker, G. D. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 238, 30-41 (2006).
40. Madeddu, C. et al. Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer. J Cell Mol Med. 18, 2519-2529 (2014).
41. Suman, S. et al. Current perspectives of molecular pathways involved in chronic Inflammation-mediated breast cancer. Biochem Biophys Res Commun. doi: 10.1016/j.bbrc.2015.10.133 (2015).
42. Hardaway, A. L. & Podgorski, I. IL-1β , RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med Chem. 5, 1089-108 (2013).
43. Ma, L. et al. Epidermal growth factor (EGF) and interleukin (IL)-1β synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion. Mol Cancer. 11, 79 (2012).
44. Reed, J. R., Leon, R. P., Hall, M. K. & Schwertfeger, K. L. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res. 11, R21 (2009).
45. Perrier, S., Caldefie-Chezet, F. & Vasson, M. P. IL-1 family in breast cancer: Potential interplay with leptin and other adipocytokines. FEBS Letters 583, 259-265 (2009).
46. Wang, F. M. et al. SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1β in vivo and in vitro. Breast Cancer Res. Treat. 89, 5-14 (2005).
47. Madeo, A. & Maggiolini, M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res. 70, 6036-46 (2010).
48. De Francesco, E. M. et al. HIF-1α /GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res. 15, R64 (2013).
49. Rigiracciolo, D. C. et al. Copper activates HIF-1α /GPER/VEGF signalling in cancer cells. Oncotarget 6, 34158-77 (2015).
50. Weienborn, C. et al. GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells. J. Cancer Res. Clin. Oncol. 140, 663-71 (2014).
51. Arias-Pulido, H. et al. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res. Treat. 123, 51-8 (2010).
52. Bartella, V., De Marco, P., Malaguarnera, R., Belfiore, A. & Maggiolini, M. New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signalling in cancer. Cell. Signal. 24, 1515-1521 (2012).
53. Ignatov, A. et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res. Treat. 128, 457-66 (2011).
54. Marjon, N. A., Hu, C., Hathaway, H. J. & Prossnitz, E. R. G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis. Mol. Cancer Res. 12, 1644-54 (2014).
55. Smith, H. O. et al. GPR30 predicts poor survival for ovarian cancer. Gynecol. Oncol. 114, 465-71 (2009).
56. Smith, H. O. et al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am. J. Obstet. Gynecol. 196, 386 e1-9 (2007).
57. Filardo, E. J. et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res. 12, 6359-66 (2006).
58. Sjostrom, M. et al. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent longterm prognosis in breast cancer. Breast Cancer Res. Treat. 145, 61-71 (2014).
59. De Marco, P. et al. Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene 32, 678-88 (2013).
60. De Marco, P. et al. GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. Endocr. Relat. Cancer. 21, 739-53 (2014).